Orphan drug prices face growing scrutiny

01/4/2013 | Reuters

High prices for orphan drugs are getting a closer look as more drugmakers develop therapies to treat rare diseases. "Health care systems around the world are under increasing financial pressure, and all of them are starting to look very carefully at what they get for their money," said health economics professor Karl Claxton.

View Full Article in:


Published in Brief: